UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancer

Annals of oncology, 2021-12, Vol.32 (12), p.1597-1607

2021

Volltextzugriff (PDF)

First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update

ESMO open, 2021-10, Vol.6 (5), p.100273, Article 100273

2021

Volltextzugriff (PDF)

Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer

Annals of oncology, 2008-02, Vol.19 (2), p.362-369

2008

Volltextzugriff (PDF)

Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer

Annals of oncology, 2018-08, Vol.29 (8), p.1701-1709

2018

Volltextzugriff (PDF)

Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study

Annals of oncology, 2018-11, Vol.29 (11), p.2214-2222

2018

Volltextzugriff (PDF)

Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study

Annals of oncology, 2020-08, Vol.31 (8), p.1056-1064

2020

Volltextzugriff (PDF)

Treatment sequences in EGFR mutant advanced NSCLC

Lung cancer (Amsterdam, Netherlands), 2024-08, Vol.194, p.107895, Article 107895

2024

Volltextzugriff (PDF)

Effectiveness of PD-(L)1 inhibitors alone or in combination with platinum-doublet chemotherapy in first-line (1L) non-squamous non-small-cell lung cancer (Nsq-NSCLC) with PD-L1-high expression using real-world data

Annals of oncology, 2022-05, Vol.33 (5), p.511-521

2022

Volltextzugriff (PDF)

Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial

Annals of oncology, 2019-12, Vol.30 (12), p.1985-1991

2019

Volltextzugriff (PDF)

Antibody–drug conjugates in lung and breast cancer: current evidence and future directions—a position statement from the ETOP IBCSG Partners Foundation

Annals of oncology, 2024-07, Vol.35 (7), p.607-629

2024

Volltextzugriff (PDF)

Impact of Continuing First-Line EGFR Tyrosine Kinase Inhibitor Therapy Beyond RECIST Disease Progression in Patients with Advanced EGFR-Mutated Non-Small-Cell Lung Cancer (NSCLC): Retrospective GFPC 04-13 Study

Targeted oncology, 2016-04, Vol.11 (2), p.167-174

2016

Volltextzugriff (PDF)

Summary of the Standards, Options and Recommendations for the management of patients with carcinoma of unknown primary site (2002)

British journal of cancer, 2003-08, Vol.89 (S1), p.S59-S66

2003

Volltextzugriff (PDF)

Early Variations of Circulating Interleukin-6 and Interleukin-10 Levels During Thoracic Radiotherapy Are Predictive for Radiation Pneumonitis

Journal of clinical oncology, 2005-12, Vol.23 (34), p.8748-8756

2005

Volltextzugriff (PDF)

Does Age Play a Role in Clinical Presentation of Hypothyroidism?

Journal of the American Geriatrics Society, 1994-09, Vol.42 (9), p.984-986

1994

Volltextzugriff (PDF)

Phase II trial of temozolomide and cisplatin followed by whole brain radiotherapy in non-small-cell lung cancer patients with brain metastases: a GLOT-GFPC study

Annals of oncology, 2006-09, Vol.17 (9), p.1412-1417

2006

Volltextzugriff (PDF)

Tumor-bronchial actinomycosis simulating a recurrence of lung cancer 14 years after initial treatment: A case report

Revue des maladies respiratoires, 2015-05, Vol.32 (5), p.524

2015

Volltextzugriff (PDF)

Assessment of a tool for decision making in case of worsening condition of cancer patients

Revue des maladies respiratoires, 2015-01, Vol.32 (1), p.66

2015

Volltextzugriff (PDF)

An open multicenter phase II trial of docetaxel–gemcitabine in Charlson score and performance status (PS) selected elderly patients with stage IIIB pleura/IV non-small-cell lung cancer (NSCLC): The GFPC 02-02a study

Critical reviews in oncology/hematology, 2007-10, Vol.64 (1), p.73-81

2007

Volltextzugriff (PDF)

Is presentation of bacteremia in the elderly the same as in younger patients?

The American journal of medicine, 1996, Vol.100 (1), p.65-70

1996

Volltextzugriff (PDF)

Late revelation of air embolism after transthoracic needle biopsy

La revue de medecine interne, 2012-04, Vol.33 (4), p.223-226

2012

Volltextzugriff (PDF)

Dramatic improvement after rituximab in a patient with paraneoplastic treatment-refractory Morvan syndrome associated with anti-CASPR2 antibodies

European journal of neurology, 2013-07, Vol.20 (7), p.e96-e97

2013

Volltextzugriff (PDF)

Randomized multicentric phase II study of carboplatin /gemcitabine and cisplatin/vinorelbine in advanced non-small cell lung cancer GFPC 99-01 study (Groupe français de pneumo-cancérologie)

Lung cancer (Amsterdam, Netherlands), 2006, Vol.51 (1), p.105-114

2006

Volltextzugriff (PDF)

Carboplatin—etoposide combination in small cell lung cancer patients older than 70 years: a phase II trial

Lung cancer (Amsterdam, Netherlands), 2002, Vol.35 (1), p.1-7

2002

Volltextzugriff (PDF)

Cost-minimization analysis of a phase III trial comparing concurrent versus sequential radiochemotherapy for locally advanced non-small-cell lung cancer (GFPC-GLOT 95–01)

Annals of oncology, 2006-08, Vol.17 (8), p.1269-1274

2006

Volltextzugriff (PDF)

Limited forms of treatment for small-cell cancers

Revue des maladies respiratoires, 1999-01, Vol.16 Suppl 3, p.S147-S149

Perol, M

1999

Volltextzugriff (PDF)

1 – 25 von 314

Suche als RSS-Feed

Aktive Filter

ThemaHumans

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(200)
Mit Volltextzugriff
(124)

Publikationsform

Sprache

Französisch
(186)
Englisch
(128)

Erscheinungsjahr

n.n

Thema

Female
(161)
Male
(154)
Life Sciences & Biomedicine
(142)
Science & Technology
(142)
Adult
(127)
Middle Aged
(125)
Aged
(101)
Oncology
(72)
Lung Neoplasms - Drug Therapy
(53)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(47)
Biological And Medical Sciences
(44)
Medical Sciences
(39)
Lung Neoplasms - Pathology
(35)
Adolescent
(33)
Treatment Outcome
(31)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(29)
Life Sciences
(29)
Respiratory System
(29)
Neoplasm Staging
(28)

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancer

First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update

Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer

Predictive biomarkers for response to EGFR-directed monoclonal antibodies for advanced squamous cell lung cancer

Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study

Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study

Treatment sequences in EGFR mutant advanced NSCLC

Effectiveness of PD-(L)1 inhibitors alone or in combination with platinum-doublet chemotherapy in first-line (1L) non-squamous non-small-cell lung cancer (Nsq-NSCLC) with PD-L1-high expression using real-world data

Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial

Antibody–drug conjugates in lung and breast cancer: current evidence and future directions—a position statement from the ETOP IBCSG Partners Foundation

Impact of Continuing First-Line EGFR Tyrosine Kinase Inhibitor Therapy Beyond RECIST Disease Progression in Patients with Advanced EGFR-Mutated Non-Small-Cell Lung Cancer (NSCLC): Retrospective GFPC 04-13 Study

Summary of the Standards, Options and Recommendations for the management of patients with carcinoma of unknown primary site (2002)

Early Variations of Circulating Interleukin-6 and Interleukin-10 Levels During Thoracic Radiotherapy Are Predictive for Radiation Pneumonitis

Does Age Play a Role in Clinical Presentation of Hypothyroidism?

Phase II trial of temozolomide and cisplatin followed by whole brain radiotherapy in non-small-cell lung cancer patients with brain metastases: a GLOT-GFPC study

Tumor-bronchial actinomycosis simulating a recurrence of lung cancer 14 years after initial treatment: A case report

Assessment of a tool for decision making in case of worsening condition of cancer patients

An open multicenter phase II trial of docetaxel–gemcitabine in Charlson score and performance status (PS) selected elderly patients with stage IIIB pleura/IV non-small-cell lung cancer (NSCLC): The GFPC 02-02a study

Is presentation of bacteremia in the elderly the same as in younger patients?

Late revelation of air embolism after transthoracic needle biopsy

Dramatic improvement after rituximab in a patient with paraneoplastic treatment-refractory Morvan syndrome associated with anti-CASPR2 antibodies

Randomized multicentric phase II study of carboplatin /gemcitabine and cisplatin/vinorelbine in advanced non-small cell lung cancer GFPC 99-01 study (Groupe français de pneumo-cancérologie)

Carboplatin—etoposide combination in small cell lung cancer patients older than 70 years: a phase II trial

Cost-minimization analysis of a phase III trial comparing concurrent versus sequential radiochemotherapy for locally advanced non-small-cell lung cancer (GFPC-GLOT 95–01)

Limited forms of treatment for small-cell cancers

Aktive Filter

Suchergebnisse filtern